Even as we ve seen multiple reports of Bharat Biotech s Covaxin being equally and sometimes even more effective than its peers against Covid-19 and several of its variants, a fresh report has suggested that millions of doses of the vaccine are set to expire early next year.
The journal said that the domestically developed vaccine is “safe, well-tolerated and immunogenic in pediatric subjects.” Bharat Biotech confirmed the development in a tweet.